First-line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic Non–Small Cell Lung Cancer in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
暂无分享,去创建一个
N. Reinmuth | Ying Cheng | E. Felip | J. Jassem | J. Neely | L. Paz-Ares | T. Ciuleanu | S. Dakhil | T. John | M. Schenker | M. Reck | Shun Lu | M. Cobo | D. Balli | J. Bennouna | A. Alexandru | E. Richardet | Laura J. Eccles | S. Protsenko | B. Żurawski | K. Feeney | N. Hu | H. Mizutani | J. Menezes | O. Juan-Vidal | A. Lingua | J. Sylvester | D. Grootendorst | D. Carbone | Xiaoqing Zhang | S. Lu | Felipe Reyes-Cosmelli | Emmanuel de la Mora Jimenez